Teamer de 5 Groupes
Chaque mois il/elle apporte 5€ à 5 Groupes
Depuis le 04-06-2016 il/elle a donné 133€
Alba est une petite fille intelligente, drôle, amicale. Même si l'on devrait plutôt dire " elle était ", car le 21 mars 2016, un terrible et tragique accident en état de choc du fait d'une crise d'épilepsie, a laissé tomber Alba d'un troisième étage. Alba a pu être sauvée, mais elle a beaucoup de lésions cérébrales. Maintenant, nous avons un long processus de rééducation neurologique devant nous pour voir à quel point elle peut se rétablir et redevenir la petite fille qu'elle était. Aidez-nous !
We are a non-profit association consisting only of 28 people affected by Nemaline Myopathy and their families, distributed throughout Spain. MN is a rare neuromuscular genetic disease (1:50,000 births) without a cure and treatment, with almost non-existent study. We have managed to launch a research project. Would you help us improve the future of our beloved ones? We'll be greatly grateful! www.yonemalinica.es
Abril is a 5 year old girl diagnosed with an ultra rare degenerative neuromuscular disease called SPG52 (Spastic Paraparesis 52), currently we only know 30 diagnoses including Abril. We fight to get it investigated and to give Abril a better quality of life. Follow us on Instagram @laluchadeabril #curespg52
Potential Can is a project that arises from the need to give more visibility and find families to the races listed as PPP's being these the most discriminated races and with less possibilities of adoption not only because of the ignorance of an audience that does not know them, but for a law that harms them even more. We focus on the kennels of the province of Cádiz and work primarily in its dissemination to give them the opportunity they never had.
All of us are affected by Multiple Sclerosis, a neuroimmunologic disease that suffer 55,000 people in Spain. Every year, 1,800 new cases of MS are diagnosed in Spain. The GAEM Foundation, with the campaign "Yo doy mis pasos", wants to boost the research of biomarkers to diagnose the disease earlier, as well as to shorten the development of new treatments to improve the health of thousands of people like us. We need € 12,000 to promote our first biomarker. Will you help us?